| Title |
Comprehensive and Methodical: Diagnostic and Management Approaches to Rapidly Progressive Dementia
|
|---|---|
| Published in |
Current Treatment Options in Neurology, September 2017
|
| DOI | 10.1007/s11940-017-0474-1 |
| Pubmed ID | |
| Authors |
Supriya Mahajan, Brian S. Appleby |
| Abstract |
Purpose of review The sudden emergence of a change in cognitive abilities or behavior is an important symptom that warrants medical evaluation and may represent the early stages of a rapidly progressive dementia (RPD). To correctly ascertain the cause of RPD in a given patient, the clinician must be methodical and knowledgeable about the range of potential causes and must move forward with supportive treatment, and in some cases empiric treatment, based on clinical features alone. Recent findings Significant advances in prion disease biomarkers, the molecular features of rapidly progressive Alzheimer's disease, and new detection of autoimmune limbic encephalitis disease entities have caused a shift in the diagnostic and treatment framework of RPD. Additionally, in the past decade, emerging retrospective data have led to suggested treatments in autoimmune encephalitis that, if instituted early, can protect patients against residual deficits and disease relapse. Summary Here, we provide an integrative clinical and diagnostic treatment approach that is applicable to the various forms of RPD. We have highlighted the clinical features of selected types of RPD that have experienced advances in the last 10-15 years. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 51 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 14% |
| Student > Doctoral Student | 6 | 12% |
| Other | 4 | 8% |
| Student > Ph. D. Student | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 10 | 20% |
| Unknown | 16 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 33% |
| Neuroscience | 4 | 8% |
| Unspecified | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 7 | 14% |
| Unknown | 17 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2017.
All research outputs
#18,575,277
of 23,007,053 outputs
Outputs from Current Treatment Options in Neurology
#369
of 471 outputs
Outputs of similar age
#246,398
of 321,741 outputs
Outputs of similar age from Current Treatment Options in Neurology
#8
of 10 outputs
Altmetric has tracked 23,007,053 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 471 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 321,741 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.